Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction

• Status: Terminated
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of ranolazine, an FDA-approved medication for the treatment of angina, on heart function by using echocardiography.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Treatments: Ranolazine

Criteria

Inclusion Criteria:

• Moderate of severe diastolic dysfunction, E/Ea>12

• Preserved systolic function

• NYHA Class I-II

Exclusion Criteria:

• QTc >450 msec at enrollment

• Taking medications that prolong QT interval or are potent inhibitors of CYP3A

• Significant coronary artery disease

• Severe valvular disease

• Hepatic disease

• Severe kidney disease

• Women of childbearing age

• Prior serious ventricular arrhythmia